Báwo ni àrùn jẹjẹrẹ kòkòrò kòkòrò ṣe máa ń yọrí sí?
Àwọn nǹkan bíi mélòó kan ló máa ń pinnu bí àrùn jẹjẹrẹ náà ṣe máa yọrí sí, irú bí àrùn jẹjẹrẹ náà ṣe máa yọrí sí, ọjọ́ orí aláìsàn náà àti bí ara rẹ̀ ṣe máa le tó, àti bí àwọn sẹ́ẹ̀lì jẹjẹrẹ náà ṣe máa ń hùwà líle tó.
Ní gbogbo gbòò, àrùn jẹjẹrẹ kòkòrò kòkòrò máa ń dára, àgàgà nígbà tí wọ́n bá tètè ṣàwárí rẹ̀.
Yang X, Wang R, Xu K, Yang F, Chen Y, Zuo Z, Song B: [Knockdown of myeloid cell leukemia 1 gene inhibits the proliferation and promotes apoptosis of prostate cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017, 33 (1): 62-66.
Kubota Y, Ito K, Imai K, Yamanaka H: Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002, 50 (4): 262-9.
Li K, Zhou H, Wang F, Zhao C, Fan C, Wang J: ZBTB38 suppresses prostate cancer cell proliferation and migration via directly promoting DKK1 expression. Cell Death Dis. 2021, 12 (11): 998.
Sun HF, Wang WD, Feng L: Effect of SPAG9 on migration, invasion and prognosis of prostate cancer. Int J Clin Exp Pathol. 2017, 10 (9): 9468-9474.
Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B: Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine (Baltimore). 2020, 99 (7): e18993.
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J, Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 2019, 121 (): 200-206.
Rucci N, Angelucci A: Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014, 2014 (): 167035.
Ìyàsímímọ́: ìtọ́jú ìlera
Oju opo wẹẹbu yii ni a pese fun eto-ẹkọ ati awọn idi alaye nikan ati pe ko ṣe agbekalẹ pese imọran iṣoogun tabi awọn iṣẹ ọjọgbọn.
A ò gbọ́dọ̀ lo ìsọfúnni tó wà nínú ìwé náà láti ṣe àyẹ̀wò tàbí láti wo àìsàn tàbí àìsàn kan wò, àwọn tó bá sì ń wá ìmọ̀ràn nípa ìṣègùn fúnra wọn gbọ́dọ̀ bá dókítà tó ní ìwé àṣẹ sọ̀rọ̀.
Jọwọ ṣe akiyesi nẹtiwọọki neural ti o ṣe agbejade awọn idahun si awọn ibeere, jẹ pataki ti ko tọ nigbati o ba de si akoonu nọmba. Fun apẹẹrẹ, nọmba awọn eniyan ti a ṣe ayẹwo pẹlu aisan kan pato.
Nigbagbogbo wa imọran ti dokita rẹ tabi olupese ilera ti o ni oye miiran nipa ipo iṣoogun kan. Maṣe gbagbe imọran iṣoogun ọjọgbọn tabi idaduro ni wiwa rẹ nitori nkan ti o ti ka lori oju opo wẹẹbu yii. Ti o ba ro pe o le ni pajawiri iṣoogun, pe 911 tabi lọ si yara pajawiri ti o sunmọ julọ lẹsẹkẹsẹ. Ko si ibatan dokita-aisan ti a ṣẹda nipasẹ oju opo wẹẹbu yii tabi lilo rẹ. Bẹni BioMedLib tabi awọn oṣiṣẹ rẹ, tabi ẹnikẹni ti o ṣe alabapin si oju opo wẹẹbu yii, ṣe eyikeyi awọn aṣoju, ṣalaye tabi tumọ, pẹlu ọwọ si alaye ti a pese nibi tabi lilo rẹ.
Ìyàsímímọ́: ẹ̀tọ́ ọmọnìyàn
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) n pese atunṣe fun awọn onihun aṣẹ-aṣẹ ti o gbagbọ pe ohun elo ti o han lori Intanẹẹti ṣe ilokulo awọn ẹtọ wọn labẹ ofin aṣẹ-aṣẹ AMẸRIKA.
Ti o ba gbagbọ ni igbagbọ to dara pe eyikeyi akoonu tabi ohun elo ti o wa ni asopọ pẹlu oju opo wẹẹbu wa tabi awọn iṣẹ ṣe ilokulo aṣẹ-aṣẹ rẹ, iwọ (tabi aṣoju rẹ) le firanṣẹ akiyesi kan si wa ti o beere pe a yọ akoonu tabi ohun elo naa kuro, tabi idilọwọ iraye si rẹ.
A gbọdọ firanṣẹ awọn iwifunni ni kikọ nipasẹ imeeli (wo abala "Ibaṣepọ" fun adirẹsi imeeli).
DMCA nilo pe akiyesi rẹ ti ilokulo aṣẹ-aṣẹ ti a fi ẹsun kan pẹlu alaye wọnyi: (1) apejuwe ti iṣẹ ti o ni aṣẹ-aṣẹ ti o jẹ koko-ọrọ ti ilokulo ti a fi ẹsun kan; (2) apejuwe ti akoonu ti a fi ẹsun kan ati alaye ti o to lati gba wa laaye lati wa akoonu naa; (3) alaye olubasọrọ fun ọ, pẹlu adirẹsi rẹ, nọmba foonu ati adirẹsi imeeli; (4) alaye nipasẹ rẹ pe o ni igbagbọ rere pe akoonu ni ọna ti o ni ẹsun ti ko ni aṣẹ nipasẹ eni aṣẹ-aṣẹ, tabi aṣoju rẹ, tabi nipasẹ iṣẹ ti ofin eyikeyi;
(5) ìpolongo kan láti ọ̀dọ̀ rẹ, tí o fìdí rẹ̀ múlẹ̀ lábẹ́ ìjìyà ẹ̀rí èké, pé ìsọfúnni tó wà nínú ìkéde náà tọ̀nà àti pé o ní àṣẹ láti mú kí àwọn ẹ̀tọ́ ọmọnìyàn tí wọ́n sọ pé wọ́n ti rú ṣẹ ṣẹ;
ati (6) ibuwọlu ti ara tabi itanna ti ẹni ti o ni aṣẹ tabi eniyan ti o ni aṣẹ lati ṣiṣẹ ni orukọ ẹni ti o ni aṣẹ.
Ti o ko ba ṣafikun gbogbo alaye ti o wa loke le ja si idaduro ti ṣiṣe ẹdun rẹ.
Ìfọ̀rọ̀wérọ̀
Jọwọ fi imeeli ranṣẹ si wa pẹlu eyikeyi ibeere / imọran.
What is prognosis of prostate cancer?
The prognosis of prostate cancer depends on several factors, including the stage of the cancer, the patient's age and overall health, and the aggressiveness of the cancer cells.
In general, prostate cancer has a good prognosis, especially when caught early.
The 5-year survival rate for localized prostate cancer (cancer that has not spread beyond the prostate) is nearly 100%. However, the prognosis worsens as the cancer progresses and spreads to other parts of the body.
It is important to discuss the specific prognosis with a healthcare professional, as it can vary greatly from person to person.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Ní nǹkan bí
BioMedLib nlo awọn kọnputa adaṣe (awọn alugoridimu ẹkọ ẹrọ) lati ṣe agbejade awọn tọkọtaya ibeere ati idahun.
A bẹrẹ pẹlu awọn atẹjade biomedical miliọnu 35 ti PubMed/Medline. Pẹlupẹlu, awọn oju-iwe wẹẹbu ti RefinedWeb.
